Development of a Panel of Biomarkers for Differential Diagnosis of Multiple Sclerosis

Demyelinating diseases are a group of heterogeneous pathologies that affect the nervous system and reduce the quality of life. One of such diseases is multiple sclerosis (MS), an inflammatory autoimmune neurodegenerative disease of the central nervous system (CNS). At the initial stages, MS can mimi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Doklady. Biochemistry and biophysics Jg. 519; H. 1; S. 593 - 596
Hauptverfasser: Ovchinnikova, L. A., Dzhelad, S. S., Simaniv, T. O., Zakharova, M. N., Lomakin, Y. A., Gabibov, A. G., Illarioshkin, S. N.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Moscow Pleiades Publishing 01.12.2024
Springer Nature B.V
Schlagworte:
Accuracy
Adult
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - diagnosis
Antibodies
Antigens
Autoimmune diseases
Biochemistry
Biochemistry, Biophysics, and Molecular Biology
Biological and Medical Physics
Biomarkers
Biomarkers - blood
Biomarkers - metabolism
Biomedical and Life Sciences
Biophysics
Central nervous system
Conflicts of interest
Demyelinating diseases
Demyelination
Diagnosis, Differential
Differential diagnosis
Disease
Epstein-Barr virus
Female
Humans
Kinases
Life Sciences
Male
Middle Aged
Molecular Biology
Multiple sclerosis
Multiple Sclerosis - blood
Multiple Sclerosis - diagnosis
Multiple Sclerosis - metabolism
Nervous system
Neurodegeneration
Neurodegenerative diseases
Neuromyelitis
Neuromyelitis Optica - blood
Neuromyelitis Optica - diagnosis
Peptides
Proteins
Quality of life
Spinal cord
EBV
autoantibodies
demyelinating diseases
multiple sclerosis
MS
Epstein–Barr virus
ISSN:1607-6729, 1608-3091, 1608-3091
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Demyelinating diseases are a group of heterogeneous pathologies that affect the nervous system and reduce the quality of life. One of such diseases is multiple sclerosis (MS), an inflammatory autoimmune neurodegenerative disease of the central nervous system (CNS). At the initial stages, MS can mimic some infectious, neoplastic, genetic, metabolic, vascular, and other pathologies. Accurate differential diagnosis of this disease is important to improve the quality of life of patients and reduce possible irreversible damage to the central nervous system. In this work, we confirmed the possibility of using our previously proposed candidate panel of MS biomarkers to distinguish MS from neuromyelitis optica spectrum disorder (NMOSD) and amyotrophic lateral sclerosis (ALS). We have shown that our proposed panel (SPTAN1 601-644 + PRX 451-494 + PTK6 301-344 + LMP1 285-330 ) allows us to distinguish MS from ALS (AUC = 0.796) and NMOSD (AUC = 0.779).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1607-6729
1608-3091
1608-3091
DOI:10.1134/S160767292460060X